Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, A.
  • Vazquez, I.
  • Cuenca, I.
  • Rosa-Rosa, J.M.|||0000-0003-0806-6453
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Jimenez, C.
  • Fernandez-Mercado, M.
  • Larrayoz, M.J.
  • Gutierrez, N.C.
  • Fernandez-Guijarro, M.
  • Gonzalez-Calle, V.
  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Alegre, Adrian|||0000-0002-2423-822X
  • Escalante, F.
  • de la Rubia, Javier|||0000-0002-8354-768X
  • Teruel, A.I.
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Lopez-Jimenez, Javier|||0000-0002-2969-3002
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Puig, Noemí|||0000-0001-7535-3861
  • Paiva, Bruno|||0000-0003-1977-3815
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Calasanz, M.J.|||0000-0002-0374-3008
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Rios, R.
  • Sureda, Anna|||0000-0002-1238-6970
  • Blanchard, María Jesús
  • Martinez-Martinez, R.
  • Moraleda, J. M.
  • Bargay, Joan|||0000-0002-6739-3916
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Palomera, L.
  • Gonzalez-Montes, Y.
  • Martí, J.M.
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Arguiñano, J.M.
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Gonzalez, A.P.
  • Casado Montero, Luis Felipe|||0000-0002-8171-0674
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Preferential Genetic Pathways Lead to Relapses in Adult B-Cell Acute Lymphoblastic Leukemia

  • Navas-Acosta, Josgrey del Valle
  • Hernández-Sánchez, Alberto|||0000-0002-6601-3096
  • González, Teresa
  • Villaverde Ramiro, Ángela|||0000-0002-7337-7218
  • Santos, Sandra
  • Miguel, Cristina|||0000-0001-7359-7993
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Granada, Isabel|||0000-0002-4275-0104
  • Morgades, Mireia|||0000-0003-0295-2534
  • Sánchez, Ricardo|||0000-0002-6383-0381
  • Such, Esperanza|||0000-0001-6892-403X
  • Barrena, Susana
  • Ciudad Pizarro, Juana
  • Dávila-Valls, Julio|||0000-0002-5185-2073
  • De las Heras, Natalia|||0000-0002-5188-5350
  • García-de Coca, Alfonso|||0000-0002-4942-060X
  • Labrador, Jorge|||0000-0002-3696-0287
  • Queizán, José Antonio
  • Martín, Sandra
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Benito, Rocío|||0000-0001-9781-4198
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
Adult B-cell acute lymphoblastic leukemia (B-ALL) is characterized by genetic heterogeneity and a high relapse rate, affecting over 40% of adults. However, the mechanisms leading to relapse in adults are poorly understood. Forty-four adult B-ALL patients were studied at both diagnosis and relapse by next-generation sequencing (NGS). Four main genetic pathways leading to relapse in adults were identified: IKZF1 genetic profile, RAS mutations and TP53 alterations in Ph-negative B-ALL and acquisition of ABL1 mutations in Ph-positive patients. The most frequently deleted gene at diagnosis was IKZF1 (52%), and 70% of these patients had IKZF1 profile. Notably, 88% of patients with IKZF1 at diagnosis retained this genetic profile at relapse. Conversely, the acquisition of RAS mutations or the expansion of subclones (normalized variant allele frequency < 25%) present from diagnosis were observed in 24% of Ph-negative patients at relapse. In addition, 24% of relapses in the Ph-negative cohort could potentially be driven by TP53 alterations. Of these cases, five presented from diagnosis, and four emerged at relapse, mostly as "double-hit" events involving both TP53 deletion and mutation. In Ph-positive B-ALL, the main genetic finding at relapse was the acquisition of ABL1 mutations (86%). Three clonal evolution patterns were identified: the persistent clone trajectory (25%), the expanding clone trajectory (11%) and the therapy-boosted trajectory (48%). Our results reveal the presence of preferential biological pathways leading to relapse in adult B-ALL. These findings underscore the need for personalized therapeutic strategies to improve clinical outcomes in adult patients with B-ALL.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

  • Sanoja-Flores, L.
  • Flores-Montero, J.
  • Garces, J.J.
  • Paiva, B.
  • Puig, N.
  • Garcia-Mateo, A.
  • Garcia-Sanchez, O.
  • Corral-Mateos, A.
  • Burgos, L.
  • Blanco, E.
  • Hernandez-Martin, J.
  • Pontes, R.
  • Diez-Campelo, M.
  • Millacoy, P.
  • Rodriguez-Otero, P.
  • Prosper, F.
  • Merino, J.
  • Vidriales, M.B.
  • Garcia-Sanz, R.
  • Romero, A.
  • Palomera, L.
  • Rios-Tamayo, R.
  • Perez-Andres, M.
  • Blanco, J.F.
  • Gonzalez, M.
  • van Dongen, J.J.M.
  • Durie, B.
  • Mateos, M.V.
  • San-Miguel, J.
  • Orfao, A.
Here, we investigated for the first time the frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) of newly diagnosed patients with localized and systemic plasma cell neoplasms (PCN) using next-generation flow cytometry (NGF) and correlated our findings with the distinct diagnostic and prognostic categories of the disease. Overall, 508 samples from 264 newly diagnosed PCN patients, were studied. CTPC were detected in PB of all active multiple myeloma (MM; 100%), and smoldering MM (SMM) patients (100%), and in more than half (59%) monoclonal gammopathy of undetermined significance (MGUS) cases (p < 0.0001); in contrast, CTPC were present in a small fraction of solitary plasmacytoma patients (18%). Higher numbers of CTPC in PB were associated with higher levels of BM infiltration and more adverse prognostic features, together with shorter time to progression from MGUS to MM (p < 0.0001) and a shorter survival in MM patients with active disease requiring treatment (p <= 0.03). In summary, the presence of CTPC in PB as assessed by NGF at diagnosis, emerges as a hallmark of disseminated PCN, higher numbers of PB CTPC being strongly associated with a malignant disease behavior and a poorer outcome of both MGUS and MM.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

  • Medina, Alejandro
  • Jimenez, Cristina
  • Sarasquete, Maria Eugenia
  • González, Marcos
  • Chillón, M. Carmen
  • Balanzategui, Ana
  • Gironella Mesa, Mercedes
Investigació genètica; Mieloma, Investigación genética; Mieloma, Genetics research; Myeloma, Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers., This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program. The authors wish to thank José Pérez, Alicia Antón, Montserrat Hernández-Ruano, Estrella Arnés, Rebeca Maldonado, Mercedes Jiménez, Alejandra Martín, Isabel Sánchez, Rocío Corral and Francisco Boix (University Hospital of Salamanca, Spain) for their technical support, as well as the Spanish Multiple Myeloma “GEM-PETHEMA” group for providing clinical data. The authors are also very grateful to the patients who participated in this study.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

  • Medina, Alejandro|||0000-0001-5609-2969
  • Puig, Noemí|||0000-0001-7535-3861
  • Flores-Montero, Juan|||0000-0002-1119-4387
  • Jimenez, Cristina
  • Sarasquete, M. Eugenia|||0000-0001-7335-3657
  • García-Álvarez, María|||0000-0001-8864-1168
  • Prieto-Conde, Isabel|||0000-0002-2510-8355
  • Chillon, Carmen
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Gutierrez, Norma C.
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosinol, Laura
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernandez, Miguel T.
  • Gonzalez-Calle, Verónica
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Paiva, Bruno|||0000-0003-1977-3815
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Orfao, Alberto|||0000-0002-0007-7230
  • González, Marcos
  • García-Sanz, Ramón|||0000-0003-4120-2787
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09-0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06-0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

  • Abrisqueta, Pau|||0000-0001-9625-7422
  • Medina, Daniel
  • Villacampa Javierre, Guillermo|||0000-0003-4868-6585
  • Lu, Junyan
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Carabia, Júlia
  • Boix, Joan
  • Tazón-Vega, Barbara
  • Iacoboni, Gloria|||0000-0003-0805-9288
  • Bobillo, Sabela|||0000-0001-7381-680X
  • Marín-Niebla, Ana|||0000-0002-7592-6815
  • González, Marcos
  • Zenz, Thorsten|||0000-0001-7890-9845
  • Crespo Maull, Marta|||0000-0002-7732-7808
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P <.001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P =.007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P <.001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P <.001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression-based assay with prognostic implications in CLL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma

  • Puig, Noemí|||0000-0001-7535-3861
  • Contreras, María Teresa|||0000-0002-2264-7791
  • Agulló, Cristina
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Oriol, Albert|||0000-0001-6804-2221
  • Blanchard, María Jesús
  • Ríos-Tamayo, Rafael|||0000-0001-8193-1402
  • Martín Sánchez, Jesús|||0000-0003-4250-4824
  • Iñigo Rodríguez, María Belén
  • Sureda, Anna|||0000-0002-1238-6970
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • de la Rubia, Javier|||0000-0002-8354-768X
  • González-Calle, Verónica|||0000-0002-5493-6707
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Cabañas Perianes, Valentín|||0000-0002-6248-2549
  • Palomera, Luis|||0000-0003-0359-7191
  • Moraleda, José María|||0000-0001-9080-1466
  • Bargay, Joan|||0000-0002-6739-3916
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Paiva, Bruno|||0000-0003-1977-3815
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Mateos, M. V.|||0000-0003-2390-1218
Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with the use of highly effective therapies, the M-protein becomes frequently undetectable, and more sensitive methods had to be explored. We applied IFE and mass spectrometry (EXENT&FLC-MS) in serum samples from newly diagnosed MM patients enrolled in the PETHEMA/GEM2012MENOS65 obtained at baseline (n 5 223), and after induction (n 5 183), autologous stem cell transplantation (n 5 173), and consolidation (n 5 173). At baseline, the isotypes identified with both methods fully matched in 82.1% of samples; in the rest but 2 cases, EXENT&FLC-MS provided additional information to IFE with regards to the M-protein(s). Overall, the results of EXENT&FLC-MS and IFE were concordant in.80% of cases, being most discordances due to EXENT&FLC-MS but IFE cases. After consolidation, IFE was not able to discriminate 2 cohorts with different median progression-free survival (PFS), but EXENT&FLC-MS did so; furthermore, among IFE patients, EXENT&FLC-MS identified 2 groups with significantly different median PFS (P 5.0008). In conclusion, compared with IFE, EXENT&FLC-MS is more sensitive to detect the M-protein of patients with MM, both at baseline and during treatment, and provides a more accurate prediction of patients' outcome. This trial was registered at www.clinicaltrials.gov as #NCT01916252.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma, Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

  • Reinoso-Segura, Marta|||0000-0002-1859-9803
  • Caballero Velazquez, Teresa|||0000-0001-7487-3793
  • Herrera, Pilar|||0000-0002-4118-7110
  • Patriarca, Francesca
  • Fanin, Renato
  • Bruno, Benedetto
  • Einsele, Hermann
  • Nahi, Hareth
  • Granell, Miquel|||0000-0002-0366-3673
  • López Corral, Lucia|||0000-0003-1908-5596
  • Reguera, Juan L.
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Gahrton, Gösta
  • Pérez-Simón, José Antonio|||0000-0003-3616-6101
The use of reduced-intensity conditioning (RIC) regimens has decreased the risk of nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). In contrast, disease relapse remains the most frequent cause of treatment failure and death. Owing to both their antimyeloma effect and immunomodulatory properties, novel drugs could improve outcomes after alloSCT. This phase II European Myeloma Network trial was designed to evaluate the combination of alloSCT with novel agents. The study was conducted to evaluate the toxicity and efficacy of RIC intensified with bortezomib (Bz) prior to alloSCT for high-risk (HR) multiple myeloma (MM) patients, as well as the efficacy of post-transplantation maintenance with Bz and lenalidomide (Len). Patients received RIC with Bz on days -9 and -2, fludarabine on days -6 to -4, and melphalan on day -3. Patients who were in complete response (CR) or near CR at day +100 post-transplantation received 6 cycles of Bz every 56 days, and the remaining received Bz, Len, and dexamethasone. Len maintenance was started on day +180 at a dose of 5 mg and continued until relapse or toxicity occurred. Of the 24 patients included, 21 were evaluable on day +100, including 12 in CR, 4 in very good partial response, 3 in partial response, and 2 with relapse or progression. The cumulative incidence (CuI) of relapse was 13.6% (95% confidence interval [CI], 3.2% to 31.3%) at 1 year and 28.5% (95% CI, 11.1% to 48.9%) at 2 years. The CuI of NRM was 21.1% (95% CI, 7.4% to 39.4%) at 2 years. With a median follow-up of 39 months (range, 1 to 67 months), the median event-free survival (EFS) was 29 months, and median overall survival (OS) was not reached. EFS and OS at 3 years were 42.5% (95% CI, 21.9% to 61.7%) and 74.01% (95% CI, 50.9% to 87.5%), respectively. The use of Bz within an RIC regimen allows for a high response rate after alloSCT. Maintenance with Bz and Len is feasible and provides remarkable results in terms of EFS and OS in HR MM patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis

  • Moreno, María José
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Novelli, Silvana|||0000-0001-8750-0195
  • Mozos, Ana|||0000-0002-3350-1827
  • Aragó, Marc|||0000-0002-9645-0131
  • Pavón, Miguel Ángel|||0000-0003-3677-5329
  • Céspedes, María Virtudes|||0000-0003-2956-5833
  • Pallarès, Victor|||0000-0002-9851-0345
  • Falgàs, Aïda|||0000-0002-5040-2265
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Blanco, Oscar
  • González-Díaz, Marcos
  • Malouf Sierra, Jorge|||0000-0001-5185-520X
  • Mangues, Ramon|||0000-0003-2661-9525
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
The CXCR4/CXCL12 axis has been extensively associated with different types of cancer correlating with higher aggressiveness and metastasis. In diffuse large B-cell lymphoma (DLBCL), the expression of the chemokine receptor CXCR4 is involved in the dissemination of malignant B cells and is a marker of poor prognosis. CXCR7 is a chemokine receptor that binds to the same ligand as CXCR4 and regulates de CXCR4-CXCL12 axis. These findings together with the report of CXCR7 prognostic value in several tumor types, led us to evaluate the expression of CXCR7 in diffuse large B-cell lymphoma biopsies. Here, we describe that CXCR7 receptor is an independent prognostic factor that associates with good clinical outcome. Moreover, the expression of CXCR7 associates with increased survival in CXCR4 + but not in CXCR4- DLBCL patients. Thus, the combined immunohistochemical evaluation of both CXCR7 and CXCR4 expression in DLBCL biopsies may improve their prognostic value as single markers. Finally, we show that CXCR7 overexpression in vitro is able to diminish DLBCL cell survival and increase their sensitivity to antitumor drugs. Hence, further studies on the CXCR7 receptor may establish its role in DLBCL and the molecular mechanisms that modulate CXCR4 activity.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

  • Medina, Alejandro
  • Jimenez, Cristina
  • Sarasquete, Maria Eugenia
  • González, Marcos
  • Chillón, M. Carmen
  • Balanzategui, Ana
  • Gironella Mesa, Mercedes
Investigació genètica; Mieloma, Investigación genética; Mieloma, Genetics research; Myeloma, Multiple myeloma is a heterogeneous disease whose pathogenesis has not been completely elucidated. Although B-cell receptors play a crucial role in myeloma pathogenesis, the impact of clonal immunoglobulin heavy-chain features in the outcome has not been extensively explored. Here we present the characterization of complete heavy-chain gene rearrangements in 413 myeloma patients treated in Spanish trials, including 113 patients characterized by next-generation sequencing. Compared to the normal B-cell repertoire, gene selection was biased in myeloma, with significant overrepresentation of IGHV3, IGHD2 and IGHD3, as well as IGHJ4 gene groups. Hypermutation was high in our patients (median: 8.8%). Interestingly, regarding patients who are not candidates for transplantation, a high hypermutation rate (≥7%) and the use of IGHD2 and IGHD3 groups were associated with improved prognostic features and longer survival rates in the univariate analyses. Multivariate analysis revealed prolonged progression-free survival rates for patients using IGHD2/IGHD3 groups (HR: 0.552, 95% CI: 0.361−0.845, p = 0.006), as well as prolonged overall survival rates for patients with hypermutation ≥7% (HR: 0.291, 95% CI: 0.137−0.618, p = 0.001). Our results provide new insights into the molecular characterization of multiple myeloma, highlighting the need to evaluate some of these clonal rearrangement characteristics as new potential prognostic markers., This work was partially supported by the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness PI15/01956, CIBERONC-CB16/12/00233, and “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010)”. M.G.-A., I.P.-C., and C.J. are supported by the Fundación Española de Hematología y Hemoterapia (FEHH, co-funded by Fundación Cris in the latter case), A.M. by the European Social Fund and the Spanish Education Council through the University of Salamanca, and M.E.S. by the ISCIII (CPII18/00028). All Spanish funding is co-sponsored by the European Union FEDER program. The authors wish to thank José Pérez, Alicia Antón, Montserrat Hernández-Ruano, Estrella Arnés, Rebeca Maldonado, Mercedes Jiménez, Alejandra Martín, Isabel Sánchez, Rocío Corral and Francisco Boix (University Hospital of Salamanca, Spain) for their technical support, as well as the Spanish Multiple Myeloma “GEM-PETHEMA” group for providing clinical data. The authors are also very grateful to the patients who participated in this study.